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1. Introduction
Haematopoiesis, the process of generation of blood cells, is one of the most extensively studied
developmental systems. The whole spectrum of blood cells produced in mammalian organ‐
isms includes primitive erythrocytes and definitive haematopoietic cells such as myeloid,
lymphoid, definitive erythroid and haematopoietic stem cells (HSCs).
Haematopoiesis takes place in several locations during ontogeny and in adult life. The
embryonic origin of blood cells has been studied for more than a century. However, studies
on haematopoiesis in vivo are challenging as embryos, and in particular mammalian embryos,
are extremely small and difficult to access at these very early stages of development. Moreover,
the number of cells per embryo is limited and all the successive developmental events take
place very fast. Therefore different approaches have been developed to facilitate these studies
in vitro and one of them involves the use of embryonic stem (ES) cell in vitro differentiation. In
this chapter, we will highlight some recent results on studies of the development of the
haematopoietic system obtained in particular using the in vitro differentiation of murine ES
cells. We will also present the methods we routinely use in our laboratory to work with wild
type or genetically modified murine ES cells.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Early haematopoietic development
2.1. How can embryonic stem cells be used to study early embryonic haematopoiesis?
Studying haematopoiesis in the mouse embryo in vivo remains challenging, in particular at the
very early stages of development when the embryo is small, difficult to access and the number
of cells is limited. One of the alternative approaches is the in vitro differentiation of ES cells
which are defined as pluripotent cells, able to give rise to three primary germ cell layers
(endoderm, mesoderm and ectoderm) [1]. ES cells are isolated from the inner cell mass of the
blastocyst and under appropriate conditions can be maintained undifferentiated in culture [2]
or alternatively allowed to differentiate. By scaling up cultures of differentiated ES cells, it is
relatively easy to access large number of cells that would be unattainable in vivo. ES cells
represent a unique tool to study the molecular and cellular mechanisms of normal haemato‐
poietic development, or the perturbations of these mechanisms leading to pathogenesis. In
addition, with the advent of human ES cells, and induced human pluripotent stem (iPS) cells,
the differentiation of these stem cells toward haematopoiesis could represent an exciting
approach to generate cell populations to treat haematological disorders.
2.2. Sites of haematopoietic development
In 1920, the embryologist Florence Sabin observed that endothelial and haematopoietic cells
were closely located in the yolk sac of avian embryo [3]. These structures, later called “blood
islands”, were thought to be derived from mesodermal cells undergoing differentiation
towards endothelial and haematopoietic lineages [4]. In the mouse embryo, the first blood cells
were shown to emerge around day E7.5 in the extra-embryonic yolk sac, within the blood
islands [5]. These first haematopoietic cells are primitive erythrocytes that transport large
amounts of oxygen required to support the rapidly growing embryo. In the final days of
gestation, their number decreases rapidly as other haematopoietic cells overtake their function.
For a long time, the yolk sac was thought to generate only primitive erythrocytes. However,
detailed studies indicated that other cell lineages such as definitive erythroid progenitors, mast
cells and bipotential granulocyte/macrophage progenitors are also generated in the murine
yolk sac before circulation [6]. By day E8.5, circulation in the mouse embryo is established and
the newly formed blood vessels connect the extra-embryonic yolk sac to intra-embryonic
tissues. From that time onward, other haematopoietic tissues within the embryo proper
become actively involved in haematopoiesis. In 1994, a seminal study by Muller and co-
workers demonstrated that at day 10 p.c. (post coitus), the aorta-gonad-mesonephros (AGM)
region contains long term repopulating haematopoietic stem cells (HSCs)-the foundation of
the blood system in adult organisms [7]. The AGM region is an intra-embryonic site that will
later develop into major internal organs. Following the discovery of these first HSCs in the
AGM region it was important to distinguish whether these cells were generated in this region
or emigrated from other embryonic locations through the blood circulation. The work of
Medvinsky and Dzierzak established that definitive HSCs, capable of long term multilineage
haematopoietic reconstitution emerge but also expand within the AGM region [8]. More
recently, the placenta, both in mouse and human was reported to contain HSCs [9, 10],
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although whether these HSCs are de novo generated within the placenta remains unknown.
During adult life, the main site of haematopoiesis is the bone marrow, where HSCs are found.
The capacity of HSCs present in the bone marrow to rebuild the whole haematopoietic
hierarchy in recipient organism is routinely used by clinicians to treat many blood-related
diseases through bone marrow transplantations.
2.3. Haemangioblast and haemogenic endothelium – Is there a connection?
The search for the cellular origin of blood cells started nearly 100 years ago, when Sabin
noticed that endothelial and haematopoietic lineages are located in close proximity within
the blood islands,  suggesting the existence of  a  common precursor  called a  haemangio‐
blast  [3].  Few years  later,  in  1924 Alexander  Maximow observed that  the  blood islands
represent mesodermal masses that differentiated towards endothelial and haematopoietic
cells [4]. In vitro experiments based on embryonic stem (ES) cell differentiation were the first
experiments  providing  substantial  data  supporting  the  existence  of  the  haemangioblast
[11-13]. First, Choi and co-workers identified a precursor called blast colony forming cell
(BL-CFC),  expressing FLK1 – the VEGR receptor  2,  that  upon culture gave rise  to  blast
colonies containing precursors for both endothelial and haematopoietic cells [11]. These BL-
CFCs were further shown to express the Brachyury (T) gene as well as the Scl (Stem Cell
Leukaemia) transcription factor [12, 13]. Later, studies on mouse embryos demonstrated the
existence of  the hemangioblast  in vivo  and indicated that it  is  found prominently in the
posterior primitive streak [14]. It probably migrates from there to the yolk sac where the
generation  of  blood,  endothelial  and  vascular  smooth  muscle  cells  take  place  [14].  The
existence of haemangioblast was also more recently documented in human with human ES
cells [15] and in vivo in zebrafish [16].
Another concept of development proposes that a mature endothelial cell with haematopoietic
potential, a haemogenic endothelium, give rise to blood cells. Several in vitro studies demon‐
strated that endothelial cells have the potential to generate blood cell lineages [17, 18]. In these
studies, the authors isolated cells expressing both FLK1 and the endothelial marker VE-
Cadherin and observed that these cells were able of de novo production of blood cells, marked
by the expression of CD45. The generation of blood cells from endothelial progenitors was also
demonstrated in vivo by Jaffredo and collaborators [19]. These authors specifically labelled
endothelial cells in the avian embryo and observed that haematopoietic cells are later generated
from these fluorescent endothelial progenitors.
More recently, a study by Lancrin and colleagues merged the haemangioblast and haemogenic
endothelium theories into one linear model of development, in which the haemogenic
endothelium is an intermediate stage during the generation of blood progenitors from the
haemangioblast [20]. The presence of a haemogenic endothelium cell population was estab‐
lished both in vitro during ES cell differentiation as well as in vivo, in E7.5 mouse embryos
[20-22]. In 2010, the generation of blood cells by haemogenic endothelium was directly
visualised in embryos. This endothelial to haematopoietic transition (EHT) was observed both
during murine [23] and zebrafish embryogenesis [24-26]. A schematic representation of the
successive stages of haematopoietic commitment is presented in Figure 1.
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Figure 1. The process of generation of blood cells from the haemangioblast through a transient haemogenic endo‐
thelium cell population. Specific markers for each cell population are depicted. This figure has been adapted from
[27].
2.4. Primitive erythrocytes – First blood cells in the embryo
Primitive erythrocytes, the first blood cells that emerge during embryogenesis in mammals,
are large and nucleated. Their main function is to transport large quantities of oxygen to
support the rapid growth of the embryo. It has been shown that these cells firstly appear in
vivo in the yolk sac’s blood islands around day E7.5 [28]. Although it was initially thought that
these cells were nucleated, more recent studies have indicated that their nuclei are lost during
the final days of mammalian gestation [29]. Studying primitive erythropoiesis remains
challenging for several reasons; not only is the murine embryo around day 7 of gestation
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extremely small and difficult to access, but also there are no specific cell surface markers to
specifically label this cell population. Therefore, transgenic mouse models were developed to
directly address this later limitation.
Two mouse models used the expression of the same haemoglobin – ε-globin, as a reporter
to track primitive erythropoiesis during ontogeny. In the first model [30], the authors coupled
the ε-globin promoter to the KGFP (jellyfish-derived) fluorescent protein. With this new tool,
they were able to isolate circulating primitive erythrocytes at  different  stages of  murine
embryogenesis  and  also  to  define  the  cell  surface  markers  expressed  by  these  cells  be‐
tween day E9.5 and E12.5 such as TER119, CD71, CD24, CD55 or CD147 [30]. In a second
model,  the  fluorescent  reporter  used  was  a  H2B-EGFP  fusion  protein  [31].  This  model
allowed study of the complex process of maturation of primitive erythrocytes within the
foetal  liver  [31].  More  recently,  the  same  group  monitored  the  emergence  of  primitive
erythrocytes at the very early stages of development in vivo, starting from day E6.75 and
defined key pathways governing the emergence of this cellular lineage [32]. Other studies
have more  directly  examined the  cell  signalling  pathways  supporting the  emergence  of
primitive erythrocytes using both in vivo mouse models, as well as in vitro using the ES cell
differentiation approach. In 2008, the importance of Wnt signalling for the emergence of
primitive erythrocytes from FLK1 positive mesoderm was demonstrated [33]. Later, Cheng
and co-workers expanded those findings and showed that not only the activation of Wnt
pathway is crucial, but also the inhibition of Notch signalling is important for the emer‐
gence of primitive erythrocytes from FLK1 positive cells [34].
2.5. In vivo studies of the first haematopoietic stem cells (HSCs) – the foundation of the
adult blood system
There are several definitive haematopoietic lineages generated during embryogenesis such as
myeloid, lymphoid, definitive erythroid and haematopoietic stem cells. HSCs are the founda‐
tion of the blood system in the adult organism as these cells can differentiate towards all
definitive haematopoietic cells.
HSCs arise first in the AGM, they possess the ability to self renew and, upon transplantation,
they provide multilineage haematopoietic reconstitution [35]. Various studies, spanning
several decades, aimed to characterise HSCs. In 1993, Huang and Auerbach reported that at
E9.0 the murine yolk sac contains HSCs [36]. These cells, however, were unable to provide
long-term multilineage haematopoietic reconstitution. A few months later, Muller and co-
workers demonstrated that at day E10.5 the AGM region of the mouse contains fully functional
HSCs – able to provide long-term haematopoietic reconstitution [7]. These findings were then
expanded and HSCs were shown to emerge and expand within the anterior part of the AGM
region [8]. It was also observed that definitive HSCs are present in the placenta, both in mouse
[9, 37, 38] and human [10]. Interestingly, more recently mouse embryonic head tissues were
shown to contain HSCs [39].
Several research groups investigated the cellular origin of haematopoietic stem cells in vivo.
Zovein and co-workers (2008) demonstrated that HSCs emerge from the endothelium by
performing lineage tracing experiment to specifically label either the endothelium or mesen‐
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chyme [21]. Furthermore, the emergence of putative haematopoietic cells from haemogenic
endothelium has been visualised in the mouse embryonic aorta [23]. Similar results were
obtained in zebrafish [24-26]. However whether these blood cells display any long-term
repopulation activity remains to be directly assessed.
2.6. Molecular regulation of early embryonic haematopoiesis
Specific transcription factors regulate the developmental potential of different cells and
progenitors during blood formation. In this section, we will discuss the role and function of a
restricted set of these players.
One of the first genes implicated in mesoderm leading to blood development is the Brachyu‐
ry gene. This transcription factor belongs to the T-box gene family [40] and is expressed by all
nascent mesodermal cells [41]. Its expression is detected in murine embryo as early as E6.5 [42]
and its deletion results in serious developmental defects and lethality by midgestation [42,
43]. In 2003, Fehling and co-workers generated a transgenic ES cell line in which GFP was
targeted to the Brachyury locus. Further differentiation of this ES cell line allowed them to
isolate mesodermal cells. The authors demonstrated that when combined with FLK1 (Fetal
Liver Kinase 1) it was possible to separate three distinct populations corresponding to pre-
mesoderm (negative for both FLK1 and Brachyury), mesodermal (positive for Brachyury only)
and finally haemangioblastic, positive for both FLK1 and Brachyury, populations [13].
Flk1 encodes the receptor 2 for vascular endothelial growth factor (VEGF-R2) [44]. This gene
is expressed by intra-and extra-embryonic mesoderm and later by endothelial cells in the
vasculature [45, 46]. In 1995, Shalaby and colleagues demonstrated that in Flk1 deficient
embryos blood vessels and blood islands are not formed and that hardly any haematopoietic
progenitors are present in these embryos [47]. As a result, Flk1 deletion is embryonic lethal
and embryos die between day E8.5 and E9.5 [47]. A few years later, they also determined, by
evaluating the contribution of Flk1 deficient ES cells to chimaeric mice, that the expression of
Flk1 is crucial for the migration of mesodermal progenitors from the intra-embryonic locations
to the yolk sac [44]. This finding was later confirmed using in vitro differentiation of ES cells.
In 1998 Choi and co-workers demonstrated that during ES cell differentiation, Flk1 expression
marks the blast colony-forming cell (BL-CFC) [11]. Later, it was shown that although Flk1
deficient ES cells are able to give rise to endothelial and haematopoietic lineages upon in
vitro differentiation, they generate reduced number of blast colonies [48]. To date FLK1
remains, with Brachyury, the best marker of haemangioblast.
Etv2, a transcription factor of the Ets family, is another important regulator of haematopoietic
specification. Murine embryos deficient for the expression of Etv2 were shown to die at around
E10.5 and to lack blood cells and vessels [49]. More recently, it was shown that Etv2 is not
required for the specification of primitive mesoderm, but is indispensable in the commitment
of FLK1-positive mesoderm towards haematopoietic and endothelial programmes [50]. Using
a transgenic Etv2 ES cell line and mouse line it was shown that the expression of Etv2 marks
the endothelium and in particular haemogenic endothelial cell population [51]. In the absence
of this transcription factor, both in vivo and in vitro, no haemogenic endothelium was observed
[51]. Furthermore, it was demonstrated using a Cre-mediated deletion of Etv2, that this
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transcription factor is acting at the Flk1 stage and that re-introduction of the Scl transcription
factor in Etv2-deficient ES cells can fully rescue the haematopoietic potential of these cells [52].
The transcription factor Scl (Stem Cell Leukaemia Factor) was originally identified due to its
involvement in chromosomal translocation in T-cell leukaemias [53] and was later demon‐
strated by both in vitro and in vivo studies to play a significant role during embryonic blood
development. Murine embryos lacking this transcription factor do not develop neither
primitive nor definitive haematopoietic cells and die by E9.5 [54, 55]. In addition, Scl-/-ES cells
do not generate blast colonies (Robertson et al., 2000) or any haematopoietic cells [56]. Blast
colony forming cells (BL-CFCs) were shown to express Scl during in vitro ES cell differentiation
[12]. More recently it was demonstrated that Scl is critical for the generation of the haemogenic
endothelium [20].
SOX7, with SOX17 and SOX18, form the F-subgroup of SRY-related (HMG-box) family of
transcription factors [57]. During embryonic development SOX7 transcripts are detected in
various tissues such as brain, heart, lung, kidney and spleen [58]. SOX7 and SOX18 knock‐
downs performed in zebrafish and Xenopus embryos revealed critical roles of these transcrip‐
tion factors in cardiogenesis and vasculogenesis [59-61]. Recently, Wat and colleagues
developed a mouse model lacking the expression of Sox7 that is embryonic lethal at E10.5 due
to cardiovascular abnormalities [62]. SOX7 was recently shown to be also implicated in early
stages of blood development. SOX7 expression is upregulated at the haemangioblast stage and
transiently expressed in the first CD41 – positive blood progenitors emerging from the FLK1-
positive haemangioblasts [63]. Its enforced expression in haematopoietic progenitors, marked
by the expression of CD41, results in the arrest of haematopoietic differentiation of these cells,
a property shared by Sox18 but not Sox17 [64]. Recently, it was also reported that SOX7 is
expressed at the haemogenic endothelium stage, where it regulates the expression of the
endothelial marker VE-Cadherin [65].
The transcription factor RUNX1, encoded by the Runx1/AML1 gene is considered a master
regulator of definitive haematopoiesis. Indeed Runx1 deficient embryos completely lack
definitive haematopoietic cells [66]. The deletion of Runx1 gene is embryonic lethal by E11.5
and E12.5 of gestation, and these embryos present multiple haemorrhages [67]. Runx1 was also
shown to be critical in vitro. Runx1-/-ES cells generate only a few blast colonies and these are
restricted to primitive haematopoietic programme [68]. Furthermore the kinetic of the
development of the haematopoietic system has been shown to be dependent of a gene dosage
effect of Runx1 [69]. Finally, Runx1 is essential for the formation of haematopoietic progenitors
from the haemogenic endothelium [20, 70, 71]. This critical role of RUNX1 in the endothelial
to haematopoietic transition has spurred efforts to identify and characterize its direct tran‐
scriptional targets [72-74].
Although, numerous molecular regulators of haematopoietic specification have been identi‐
fied, it is likely that many others remain to be discovered. In addition, the events they regulate
and how they interact to orchestrate blood development remain largely unknown. The specific
requirement for several of these regulators is depicted in Figure 2.
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Figure 2. Molecular regulation of early embryonic haematopoiesis. The stages of blood development where the
function of the different genes is critical are indicated.
3. Methods and procols to study haematopoitic development during es cell
differentiation
ES cell differentiation provides a relatively easy and accessible system to study early embry‐
onic haematopoiesis. Using well-defined protocols, it is possible to effectively study the events
happening in vivo using this in vitro approach. This experimental system was shown to
recapitulate the early in vivo events of development of the haematopoietic system.
3.1. Mouse embryonic fibroblasts (MEFs)
There are several methods to keep ES cells undifferentiated. One of them consists of growing
ES cells on mouse embryonic fibroblasts (MEFs). Before working with ES cells, it is recom‐
mended to prepare a good stock of MEFs to be used as feeder cell layer. For that, wild type
ICR or DR4 (resistant to four drugs) [75] MEFs are harvested from E14.5 embryos and cultured
in Iscove’s modified Dulbecco medium (IMDM, Lonza) supplemented with 50 µg/ml penicil‐
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lin-streptomicin (Gibco), 2mM L-Glutamine, 10% of FCS (PAA Laboratories) and 1,5x10-4
monothioglycerol (MTG, Sigma) under low oxygen conditions. When amplified, MEFs are
harvested (TrypLE, Invitrogen) and irradiated at 30Gy to stop the cells proliferation. The cells
should be frozen at around 1 million cells per ml of IMDM supplemented with 50% FCS and
10% of dimethyl sulfoxide (DMSO). Cells should be stored at-80 0C. Thawed MEFs should be
replated in one six-well plate previously coated with gelatine and let to adhere to the plastic
wells overnight. Upon microscopic examination, MEFs should cover the entire surface of the
cell-culture dish and be ready to be seeded with ES cells.
3.2. ES cell culture
ES cells are cultured on irradiated MEFs in a media constituted of Dulbeco’s modified Eagle
Medium (DMEM, Gibco) supplemented with 50 µg/ml penicillin-streptomycin, 2mM L-
Glutamine, 15% FCS (PAA Laboratories), 2% Leukaemia Inhibitory Factor (LIF) (conditioned
medium from LIF-generating cell line, see [76]) or 50 units of recombinant ESGRO LIF/ml
(Millipore) and 1,5x104 MTG (Sigma). Leukaemia inhibitory factor (LIF) – is a cytokine
inhibiting differentiation. ES cells, when cultured on MEFs feeder cell layer in the presence of
LIF remain undifferentiated. Upon microscopic observation they form tightly associated
clusters of cells that are bright and shiny in appearance (Fig. 3A).
3.3. Generation of embryoid bodies
Embryoid bodies (EBs) are three-dimensional structures spontaneously generated by ES cells
during differentiation. They contain precursors for the three primary germ layers ectoderm,
endoderm and mesoderm. Two passages on gelatine are performed to remove the MEFs that
would hamper ES cells differentiation. The first passage is performed in DMEM-ES media
(described above), whereas for the second passage DMEM is replaced with IMDM. The ES
cells are then harvested by trypsinisation and seeded into liquid cultures in non-tissue culture
Petri dishes (Sterilin) in differentiation medium containing: IMDM supplemented with 15%
FCS serum selected for differentiation (PAA Laboratories), 2mM L-Glutamine, 180 µg/ml
transferring (Roche), 25 µg/ml Ascorbic Acid (AA, Sigma) and 4,6x10-4 MTG. The density of
cell seeding should be adjusted in function of the day at which the cultures will be harvested,
varying from 1,5x104 cells/ml (for day 4-6) up to 3,0 x 104 cells/ml (for days 2.5-3.5). 10-20ml of
“Differentiation medium” should be used per one Petri dish.
By performing two passages on gelatine and removing feeder cell layer and LIF, ES cells
become primed for differentiation and formation of three-dimensional embryoid bodies in
liquid culture (Figure 3B). Early EBs contain precursors for the three primary germ layers. By
day 7, hemoglobinisation can be observed as red areas present within the EBs (Figure 3C). This
system is versatile and allows to access and study in details several subsequent stages of blood
development such as the emergence of haemangioblast, production of blast colonies and the
development of primitive and definitive blood precursors (Figure 4).
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Figure 3. Morphology of ES cells and embryoid bodies (EBs). A) Typical appearance of ES cell in culture. Cells form
bright, shiny adherent colonies and are cultured on a layer of MEFs feeder cell layer. B) Typical appearance of EBs in
culture. These three-dimensional structures are formed during ES cell differentiation and contain precursors for three
primary germ cell layers. C) Embryoid bodies at day 7 of differentiation containing haemoglobin (indicated with aster‐
isks). Scale bar 300µm.
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Figure 4. The ES/EB differentiation system. Upon differentiation of ES cells, three-dimensional structures, called em‐
bryoid bodies (EBs) are formed. Sorting EBs at day 2.5-3.5 for the expression of FLK1 enrich for BL-CFC, the in vitro
equivalent of the haemangioblast. Upon culture, the BL-CFCs generate blast colonies that contain precursors for hae‐
matopoietic, endothelial and vascular smooth muscle cells. Day 4-6 EBs contain haematopoietic progenitors that can
give rise to various primitive and definitive haematopoietic colonies.
3.4. Blast colonies
There are two alternative approaches to study the development of blast colonies; liquid culture
on gelatine or semi-solid culture in methylcellulose. Liquid culture on gelatine facilitates
harvesting of the cells for flow cytometry analysis or time-lapse imaging techniques. Alterna‐
tively, the semi-solid culture is a clonogenic assay allowing the growth of of individual blast
colonies and their quantification. Individual blast colonies can then further be isolated and
their haematopoietic potential assessed. To perform blast colony culture, EBs are harvested
between day 2.5 and 3.5 and the cells are enriched for haemangioblast by sorting for the
expression of FLK1, the receptor 2 for VEGF. Isolated FLK1 positive cells are then replated on
gelatinised cell culture plates at the density of 8,5 x 104 cell/10cm2 in a medium containing
IMDM supplemented with 10% FCS, 2mM L-Glutamine mM, 180 µg/ml transferrin, 25 µg/ml
ascorbic acid, 4.6 x 10-4 M MTG, 15% endothelial cell line-D4T conditioned medium [11], 10
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ng/ml interleukin 6 (IL-6) (Peprotech) and 5 ng/ml vascular endothelial growth factor (VEGF,
Peprotech). For semi-solid cultures, FLK1 positive cells are seeded in 35 mm x 10 mm (BD
Falcon) dishes at a density of 1.5 x 104 cells/ml in IMDM medium supplemented with 10% FCS,
2mM L-Glutamine mM, 180 µg/ml transferrin, 25 µg/ml ascorbic acid, 4.6 x 10-4 M MTG, 15%
endothelial cell line-D4T conditioned medium [11], 10 ng/ml interleukin 6 (IL-6) (Peprotech)
and 5 ng/ml vascular endothelial growth factor (VEGF, Peprotech). The medium is additionally
supplemented with 10 g/L methylcellulose (dissolved in IMDM, Alfa-Aesar). Blast colonies
are scored 3-4 days after replating. Plating 3.0 x 104 cells per 1 ml of semi-solid medium should
result in the formation of around 300-400 of blast colonies.
Sorting EBs between day 2.5 and 3.5 for the expression of FLK1 enrich for blast colony forming
cell (BL-CFCs) [11, 13]. During the formation of blast colonies, several distinct morphological
stages can be observed. First, there is the formation of tight clusters of adherent cells and later,
single round cells emerging from these tight clusters. These cells then proliferate (Figure 5A).
Alongside these morphological changes, there is first an upregulation of endothelial markers,
such as TIE2 and VE-Cadherin during the formation of the tight clusters. Later the expression
of these endothelial markers is gradually downregulated whereas the expression of haema‐
topoietic markers (such as CD41 and then CD45) is upregulated (Figure 5B). This correlates
with the emergence of round floating–haematopoietic-cells.
Figure 5. The development of the blast colony during four days of differentiation. A) Microscopic image showing
representative blast colonies. Scale bar 100µm. B) Schematic representation of the different cell surface markers ex‐
pressed on cells during blast colony differentiation.
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It was recently shown that the haemangioblast progenitor can also generate vascular smooth
muscle cells in addition to endothelial and haematopoietic cells [14, 77, 78]. Accordingly,
Yamashita and co-workers also established that FLK1 positive cells can differentiate towards
endothelial and mural cells [78]. Smooth muscle cells appear, under the microscope as large
flat adherent cells. These cells express smooth muscle specific genes such as smooth muscle
actin α, transgelin, calponin, and smooth muscle myosin heavy chain [79]. A typical immuno-
staining of α-smooth muscle actin is presented in figure 6A. We have recently analysed in more
detail the generation of smooth muscle cells and showed that these cells are largely generated
independently from the haemogenic endothelium [80].
Figure 6. The differentiation of ES cells towards smooth muscle cells. Representative image of smooth muscle
cells stained with SMAα-Cy3 antibody. These cells also carry a transgenic BAC containing H2B-VENUS cDNA under the
control of the α-smooth muscle actin transcriptional regulatory elements. Scale bar 100µm.
3.5. Culture of haemogenic endothelium
During blast colony development in vitro, tight clusters of adherent cells that represent
haemogenic endothelium are observed after around two days. This population of cells
corresponds to an intermediate stage in the formation of blood cells from the haemangioblast.
It was recently shown that these cells express TIE2 and VE-cadherin (markers of endothelial
cells), c-KIT (expressed by both haematopoietic and endothelial cells) and are negative for
CD41 (first haematopoietic marker) expression [20]. To isolate haemogenic endothelium, cells
in day 2 liquid blast cultures are harvested and FACS sorted for the expression of these markers
[20]. It is also possible to isolate a more advanced haemogenic endothelium cell population,
positive for the expression of CD41 [70]. The cells are next plated onto gelatin-coated plates at
a density of 1.2 x 105 cells/cm2 in IMDM medium supplemented with 10% FCS, 2 mM L-
Glutamine, 180 µg/ml transferrin, 25 µg/ml ascorbic acid, 4.6 x 10-4 M MTG, 10 ng/ml Oncos‐
tatin M (R&D Systems) and 1 ng/ml bFGF (Peprotech). Cells are grown in standard culture
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conditions. Upon culture, at least 1-2% of these cells generate primitive and definitive haema‐
topoietic cells [20]. During this process, the haemogenic endothelial cell population (TIE2+,c-
KIT+,CD41-) cells gradually acquire the expression of CD41. The cells then progress further
and lose their expression of endothelial markers.
3.6. Haematopoietic colonies assays
To evaluate the presence of haematopoietic colonies, EBs should be harvested at day 4,5 or 6
and trypsinised. Cells from the EBs can be then directly used or alternatively sorted for the
expression of a marker of haematopoietic progenitors, such as for example CD41. Approxi‐
mately 3.0 x 104 unsorted cells should be plated in 35 mm x 10 mm (BD Falcon) dishes in 1 ml
of semisolid medium containing IMDM, 15% plasma derived serum (PDS) (Antech), 10%
protein free hybridoma medium (PFHM, Gibco), 2mM L-Glutamine, 180 µg/ml transferrin, 25
µg/ml ascorbic acid, 4.6 x 10-4 M MTG and cytokines such as: 1% c-KIT ligand supernatant,
1% interleukin 3 supernatant (IL-3) (see [76]), 1µg/ml GM-CSF, 1% thrombopoietin condi‐
tioned media, 10 ng/ml IL-6 (Peprotech), 10 ng/ml macrophage colony stimulating factor (M-
CSF), 5 ng/ml IL-11 (R&D Systems) and 4 U/ml of Erythropoietin (Ortho-Biotech) and 10 g/L
methylcellulose (dissolved in IMDM, Alfa-Aesar). Haematopoietic colonies are assessed and
scored based on their morphology. Primitive erythroid colonies are scored at day 5, whereas
definitive haematopoietic colonies are usually enumerated 8 days after replating. Morphologic
landmarks are used to distinguish the different types of haematopoietic colonies. Haemato‐
poietic progenitors can also be cultured in liquid conditions to allow easier access of the cells
for subsequent flow cytometry analysis or cytospin assays. For that cells should be seeded at
a density of 2.0 x 106 /ml in ultra low-adherence tissue culture plates (Costar) in the haemato‐
poietic medium described above with methylcellulose being replaced with IDMD medium.
The onset of emergence of primitive erythroid cells is observed within EBs by day 4 of
differentiation [81]. Definitive erythroid and macrophage precursors appear shortly after and
are followed by mast cells and multilineage precursors [81]. Primitive colonies appear around
day 4 of culture. These colonies are round, compact and bright red in colour. By day 6-7 of
culture, morphologically distinguishable definitive haematopoietic colonies are detected
(Figure 7).
4. Conclusions and future directions
In this chapter, we have reviewed recent progress in our understanding of the development
of the haematopoietic system. We have emphasized the critical role that the use of ES cells, in
particular murine ES cells, has played in these recent advances. ES cells have been instrumental
to identify and characterise the elusive haemangioblast. More recently, this model system
allowed the merging of the two conflicting theories of the origin of blood cells (haemangioblast
and haemogenic endothelium) in a single linear model of development. In addition the precise
roles and requirements of many critical regulators of this process have been to a large extent
elucidated using this approach.
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models78
Although only very succinctly discussed in this chapter, this system is also very amenable to
examination of the cell signalling pathways that support the development of normal haema‐
topoiesis [33, 34, 82-84]. Interestingly these pathways are also implicated in leukaemogenesis
[85, 86]. Finally with the advent of novel human ES cells or human iPS cells [87], that recapit‐
ulate better the ground state and are easier to work with, and development of new methods
facilitating genome editing [88-92], this experimental system is very likely to be instrumental
for delivering new advances in our understanding of human haematopoietic development,
that is otherwise very difficult to study in vivo.
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Figure 7. Examples of haematopoietic colonies obtained during ES cell differentiation A) Primitive erythroid colony –
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